1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42.
3. David G, Gunnarsson CL, Lofland J, Goodney P, Siegel CA. Mo1362 Geographic variation in care of patients with inflammatory bowel disease suggests unequal quality of care in the United States. Gastroenterology 2013;144(5 Suppl 1): S-647.
5. Vienne A, Simon T, Cosnes J, et al. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment Pharmacol Ther 2011;34:188-195.
6. Wilson B, Lonnfors S, Hommes DW, et al. P406 A European Crohn’s and ulcerative colitis patient life IMPACT survey. J Crohns Colitis 2012;6(Suppl 1): S171.
7. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut 2011;60:1178-1181.
8. Mikocka-Walus A, Andrews JM, Rampton D, Goodhand J, van der Woude J, Bernstein CN. How can we improve models of care in inflammatory bowel disease? An international survey of IBD health professionals. J Crohns Colitis 2014;8:1668-1674.
12. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis 2013;19:662-668.
16. Crandall W, Kappelman MD, Colletti RB, et al. ImproveCare-Now: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 2011;17:450-457.
18. Regueiro M, Click B, Holder D, Shrank W, McAnallen S, Szigethy E. Constructing an inflammatory bowel disease patient-centered medical home. Clin Gastroenterol Hepatol 2017;15:1148-1153.e4.
19. Kosinski L, Baum C, Brill J, et al. P-052 Project sonar: patient engagement reduced relative risk and cost of care in an attributed cohort of patients with Crohn’s disease. Inflamm Bowel Dis 2017;23:S22.
21. Walters S. NACC audit of IBD. Chichester: Aeneas Press, 2000.
32. Haapamäki J, Turunen U, Roine RP, Färkkilä MA, Arkkila PE. Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. Scand J Gastroenterol 2008;43:821-830.
34. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel: diagnostics guidance [DG11]. National Institute for Health and Care Excellence (NICE) Web site.
https://www.nice.org.uk/guidance/dg11. Updated 2013. Accessed March 9, 2018.
35. Walker GJ, Moore L, Heerasing N, et al. PTH-092 Clinical validity and utility of faecal calprotectin in primary care. Gut 2017;66:A252.